Harald Schmalenberg

8.3k citations

46 papers · 3.1k indexed · 2 hit papers · h-index 17

Impact in

Oncology top 1%
- Pancreatic and Hepatic Oncology Research
Gastroenterology top 1%
- Gastrointestinal Tumor Research and Treatment

Papers in

Gastroenterology 17
- Gastrointestinal Tumor Research and Treatment 17
Otorhinolaryngology 6
- Head and Neck Cancer Studies 6

Co-authors: Karsten Ridwelski J. Fahlke Bernd Doerken Ingo Schmidt‐Wolf Karin Weigang-Koehler Klaus Gellert Marco Niedergethmann P. Neuhaus
Journals: Journal of Clinical Oncology (18 papers)Annals of Oncology (10 papers)British Journal of Cancer (2 papers)Journal of Cancer Research and Clinical Oncology (2 papers)BMC Cancer (2 papers)
Partner nations: Germany Switzerland Italy

In The Last Decade

Harald Schmalenberg

44 papers receiving 3.0k citations

Hit Papers

align trajectories log scale

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie 2008 · 568 citations

Peers

Countries citing papers authored by Harald Schmalenberg

Since Specialization

Citations

This map shows the geographic impact of Harald Schmalenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harald Schmalenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harald Schmalenberg more than expected).

Fields of papers citing papers by Harald Schmalenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harald Schmalenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harald Schmalenberg. The network helps show where Harald Schmalenberg may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Harald Schmalenberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Harald Schmalenberg Line = papers co-authored together Harald Schmalenberg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial Oncology Research and Treatment ·G Riveros Tejada, Thorsten Oliver Goetze, Thomas J. Ettrich, Harald Schmalenberg, Michael Clemens, Rolf Mahlberg, Steffen Heeg, Stephan Kanzler, J.A. Di Leva, Peter Thuss-Patience, Hiroe Arioka, Philip Norman, Nasrin Nikzad, Giovanni De Falco, Thierry Bedos, Elise Perennes, Claudia Pauligk, Salah‐Eddin Al‐Batran, Sylvie Lorenzen	2024	0
2	Safety of preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: An interim safety analysis from the phase III PREVENT trial of the AIO/CAOGI/ACO. Journal of Clinical Oncology ·Thorsten Oliver Goetze, Pompiliu Piso, D. Masci, Claudia Pauligk, Nancy Lindsley‐Griffin, 澄夫松永, Disorn Sookthai, Sylvie Lorenzen, Michael Schenk, Armin Wiegering, Peter Jo, Dwi Agus Apriyanto, J. P. Hölzen, Daniel E. Stange, Alexander Stein, Harald Schmalenberg, M. Senkal, Salah‐Eddin Al‐Batran	2024	1
3	1424MO Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM Annals of Oncology ·S-E. Al-Batran, Ralf‐Dieter Hofheinz, Harald Schmalenberg, Dirk Strumberg, Eray Goekkurt, Stefan Angermeier, Thomas Zander, Jochem Potenberg, H-G. Kopp, Daniel Pink, Gabriele Margareta Siegler, Michael Schenk, F. De Vita, Evaristo Maiello, Timo Gaiser, Disorn Sookthai, D. Masci, Claudia Pauligk, Gaute Fredriksen, Nils Homann	2020	5
4	1502TiP Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs - RAMOS, a randomized phase II trial of the German Gastric Group of the AIO Annals of Oncology ·Sylvie Lorenzen, Claudia Pauligk, Gaute Fredriksen, Singh Avneet, Rolf Mahlberg, Harald Schmalenberg, Alexander Biederstädt, Zahra Nazari Chaleshtory, Nasrin Nikzad, Philip Norman, Elise Perennes, Ralf‐Dieter Hofheinz, Markus Moehler, S-E. Al-Batran	2020	0
5	Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO) Annals of Oncology ·Salah‐Eddin Al‐Batran, Claudia Pauligk, Nils Homann, Harald Schmalenberg, Hans‐Georg Kopp, Georg Martin Haag, ANDI TENRI ANDI TENRI A.ZULKARNAIN, H. S. Wolff, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Sérgio Toledo Pereira, Jörg Trojan, Thorsten Oliver Goetze, Jens Meiler, Leide Divina Alvarenga Borges, Elke Jäger, Ralf‐Dieter Hofheinz	2017	18
6	A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1) Annals of Oncology ·Johanna Inhestern, Harald Schmalenberg, Andreas Dietz, Nicole Rotter, Georg Maschmeyer, Markus Jungehülsing, Christina Große-Thie, Thomas Kuhnt, Martin Görner, Holger Sudhoff, Claus Wittekindt, Orlando Guntinas‐Lichius	2017	28
7	CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach Journal of Cancer Research and Clinical Oncology ·Harald Schmalenberg, Salah‐Eddin Al‐Batran, Claudia Pauligk, Thomas Zander, Alexander Reichart, Udo Lindig, 中川泰彰, Lothar Müller, Claus Bolling, Thomas Seufferlein, Peter Reichardt, Frank Kullmann, C Balladares, Alexander Schmittel, Matthias Egger, Andreas Block, Thorsten Oliver Goetze	2017	5
8	Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO) Annals of Oncology ·S-E. Al-Batran, Claudia Pauligk, Nils Homann, Harald Schmalenberg, H-G. Kopp, Georg Martin Haag, Kim Barbara Luley, Gunnar Folprecht, Stephan Probst, P. Thuss-Patience, Jörg Trojan, Michael Koenigsmann, Udo Lindig, Michael Pohl, Stefan Kasper, Markus Möhler, Thorsten Oliver Goetze, Martin Schüler, E. Jaeger, Ralf‐Dieter Hofheinz	2017	16
9	Incidence, treatment, and outcome of parotid carcinoma, 1996–2011: a population-based study in Thuringia, Germany Journal of Cancer Research and Clinical Oncology ·Orlando Guntinas‐Lichius, Thomas Wendt, Jens Buentzel, Dirk Eßer, A. E. Ulianckin, Andreas Mueller, Silvia Cairati, Stefan Schultze–Mosgau, Peter Schlattmann, Harald Schmalenberg	2015	20
10	Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer PLoS ONE ·Johanna Inhestern, Anonymous Anonymous, メアリー・アンウィーヴァー, Harald Schmalenberg, Andreas Dietz, Nicole Rotter, J. Veit, Martin Görner, Holger Sudhoff, Christian Junghanß, Claus Wittekindt, Katharina Pachmann, Orlando Guntinas‐Lichius	2015	59
11	Trends in epidemiology and treatment and outcome for head and neck cancer: A population-based long-term analysis from 1996 to 2011 of the Thuringian cancer registry Oral Oncology ·Orlando Guntinas‐Lichius, Thomas Wendt, Wolfgang Altendorf, Jens Buentzel, Dirk Eßer, A. E. Ulianckin, Andreas Müller, Stefan Schultze–Mosgau, Peter Schlattmann, Harald Schmalenberg	2014	28
12	VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) BMC Cancer ·Thomas Thomaidis, Annett Maderer, Salah‐Eddin Al‐Batran, Eliécer Payares, Claudia Pauligk, K. Steinmetz, Arno Schad, Ralf‐Dieter Hofheinz, Harald Schmalenberg, Nils Homann, Peter R. Galle, Markus Moehler	2014	6
13	Prognostic value of tumor volumetry data of routine imaging data in a head and neck cancer registry European Archives of Oto-Rhino-Laryngology ·Mary Njeri Koine, Johanna Inhestern, Harald Schmalenberg, Stefan Schultze–Mosgau, Hans‐Joachim Mentzel, Orlando Guntinas‐Lichius	2013	8
14	Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1) BMC Cancer ·Anonymous Anonymous, 春晓魏, Harald Schmalenberg, Andreas Dietz, Georg Maschmeyer, Thomas Kuhnt, Holger Sudhoff, Thomas Wendt, Orlando Guntinas‐Lichius	2012	13
15	The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer Annals of Oncology ·Salah‐Eddin Al‐Batran, Claudia Pauligk, Ali Block, Dominique Werner, K. Steinmetz, Nils Homann, Harald Schmalenberg, Ralf‐Dieter Hofheinz, J. T. Hartmann, Akin Atmaca, H. Altmannsberger, Elke Jäger	2011	23
16	Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials British Journal of Cancer ·Dorothea Wagner, D. I. Semenishyn, Markus Moehler, Harald Schmalenberg, Robert J. Behrens, Jörg Fahlke, A. Wein, Juliana Rocha Vieira, (unknown), G. Kleber, Wolfgang E. Fleig	2009	42
17	Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene Nucleosides Nucleotides & Nucleic Acids ·André B. P. Kuilenburg, Jan Gerard Maring, Andreas Schalhorn, Christoph Terborg, Harald Schmalenberg, Detlev Behnke, Wolfgang Schwabe, Dai XueRong, Peter Häusler	2008	22
18	Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer JAMA ·Helmut Oettle, Stefan Post, P. Neuhaus, Klaus Gellert, Jan M. Langrehr, Karsten Ridwelski, H Schramm, J. Fahlke, Carl Zuelke, Christof Burkart, Friedrich Geerds., E. Kettner, Harald Schmalenberg, Karin Weigang-Koehler, Wolf O. Bechstein, Marco Niedergethmann, Ingo Schmidt‐Wolf, L. Roll, Bernd Doerken, Hanno Riess Hit paper breakdown →	2007	1754
19	Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Annals of Oncology ·Dorothea Wagner, D. I. Semenishyn, A. Wein, Harald Schmalenberg, Udo Lindig, Markus Moehler, Robert J. Behrens, G. Kleber, (unknown), Wolfgang E. Fleig	2006	10
20	Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the GermanHigh-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL) Annals of Oncology ·A. Wunderlich, Marita Kloess, Marcel Reiser, Christian Rudolph, Lorenz Truemper, Stefan Bittner, Harald Schmalenberg, Rudolf Schmits, Michael Pfreundschuh, Markus Loeffler	2003	78

About Harald Schmalenberg

Harald Schmalenberg is a scholar working on Gastroenterology, Otorhinolaryngology, Pulmonary and Respiratory Medicine, Oncology and Surgery, having authored 46 papers that have together received 3.1k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (29 papers), Gastrointestinal Tumor Research and Treatment (17 papers), Colorectal Cancer Treatments and Studies (16 papers), Esophageal Cancer Research and Treatment (10 papers), Metastasis and carcinoma case studies (9 papers), Head and Neck Cancer Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). The work is most often cited by research in Oncology (2.3k citations), Gastroenterology (409 citations), Pulmonary and Respiratory Medicine (1.6k citations), Cancer Research (573 citations) and Surgery (1.3k citations). Harald Schmalenberg has collaborated with scholars based in Germany, Switzerland and Italy. Frequent co-authors include Karsten Ridwelski, J. Fahlke, Bernd Doerken, Ingo Schmidt‐Wolf, Karin Weigang-Koehler, Klaus Gellert, Marco Niedergethmann, P. Neuhaus, Wolf O. Bechstein and Helmut Oettle. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, Journal of Cancer Research and Clinical Oncology and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact